Clinical Trials Logo

Clinical Trial Summary

This study aims to evaluate the effectiveness of GGTCA-AD to decrease the maladaptive beliefs associated with eating disorders (ED) in non-clinical adolescent population. Specifically, a randomized controlled trial with parallel design and two groups (experimental and control) will be carried out in adolescents aged 13-15 years to assess the changes pre and post use of the app. It is expected that after the use of the GGTCA-AD app for 14 days, at the primary level, a: decrease in the degree of ascription to dysfunctional beliefs associated with ED; and at the secondary level: increase in body satisfaction and self-esteem; decrease in eating symptomatology; and no changes in emotional symptomatology. These results are also expected to be maintained in subsequent follow-up at 1 month.


Clinical Trial Description

There is a digital platform called GGtude, which is composed of different modules, each of them aimed at working with different mental health problems. The goal is to provide an easy-to-use tool as a CBT complement to work on the self-dialogue that relates to the core beliefs associated with the psychological problem in particular. To achieve this target, a cognitive training exercise is performed: different sentences appear in the form of beliefs, and the person must identify and accept those beliefs that are functional, adaptive and positive, dragging them to the lower part of the screen; and reject those that are dysfunctional, maladaptive and negative dragging them to the upper part of the screen. The GGTCA app is a module of GGtude that was developed to work on dysfunctional beliefs associated with eating disorders. Previous research showed that the app produced a statistically significant decrease of mean scores in maladaptive beliefs associated with ED and a statistically significant increase in self-esteem in adult population. Furthermore, adolescence is a developmental stage vulnerable to the development of these disorders, so it's relevant to adapt the GGTCA application to the adolescent population (GGTCA-AD) and to evaluate its effectiveness. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06039514
Study type Interventional
Source University of Valencia
Contact Gemma García Soriano
Phone 963983389
Email gemma.garcia@uv.es
Status Not yet recruiting
Phase N/A
Start date April 9, 2024
Completion date May 23, 2024

See also
  Status Clinical Trial Phase
Completed NCT04591886 - The Peer-Delivered "Mind. Body. Voice." Program for High School Women N/A
Completed NCT03097874 - Adaptive Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT04591912 - The Peer-Delivered "Mind. Body. Voice." Program for High School Women (Mbv) - Remote N/A
Completed NCT05554458 - Implementation and Evaluation of the ChildTaks+ Intervention in the Czech Republic N/A
Recruiting NCT04552639 - Evaluation of Compulsive Exercise Group Therapy for Eating Disorders N/A
Completed NCT05091983 - Restrictive Eating Disorders: From Childhood Orality Disorder to Adolescent Dysensoriality
Active, not recruiting NCT04127214 - The ITA Model of Integrated Treatment of Eating Disorders
Completed NCT04888273 - Assessing the Feasibility of an Intervention for Youth and Parents Transitioning to Adult Eating Disorder Services N/A
Recruiting NCT03563755 - Social Information Processing in Adolescents With Eating Disorders N/A
Active, not recruiting NCT05780242 - Recrudescence of Eating Conduct Disorders and Covid-19
Active, not recruiting NCT03693911 - ACT to Prevent Eating Disorders: Evaluating a Gamified Prevention Program N/A
Recruiting NCT03855553 - Project CORE: Disseminating Eating Disorders Treatment Phase 1
Completed NCT04088097 - Cognitive Behavioral Therapy for Adolescent Binge Eating and Loss of Control Eating N/A
Completed NCT04263155 - The Peer-Delivered Body Project for Young Women in High School N/A
Enrolling by invitation NCT04869423 - Animal-Assisted Therapy in Adolescents With Eating Disorders N/A
Enrolling by invitation NCT05073679 - Oral Naltrexone In Pediatric Eating Disorders Phase 2/Phase 3